Payment overview · 2025
General Payments
$754.28
7 reported records · 4 companies
Healthcare provider profile · identity verified
Michael William Vincent Ross, DO
Allopathic & Osteopathic Physicians|Family Medicine · BATAVIA, IL · NPI 1366855454
Verified facts
What the public records show
CMS Open Payments records show Michael William Vincent Ross, DO received $754.28 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $327.16 | 43.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $223.77 | 29.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.85 | 16.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $81.50 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $754.28 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $232.96 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $223.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.20 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $81.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 74 |
| Lisinopril | Lisinopril | 322 | 89 |
| Losartan Potassium | Losartan Potassium | 285 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 73 |
| Omeprazole | Omeprazole | 247 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 59 |
| Metformin Hcl | Metformin Hcl | 183 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 48 |
| Gabapentin | Gabapentin | 174 | 58 |
| Metformin Hcl Er | Metformin Hcl | 161 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 40 |
| Ezetimibe | Ezetimibe | 110 | 25 |
| Warfarin Sodium | Warfarin Sodium | 110 | 20 |
| Allopurinol | Allopurinol | 109 | 32 |
| Alprazolam | Alprazolam | 108 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 43 |
| Glipizide | Glipizide | 107 | 31 |
| Ozempic | Semaglutide | 104 | 19 |
| Sertraline Hcl | Sertraline Hcl | 97 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 15 |
| Simvastatin | Simvastatin | 96 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 21 |
| Jardiance | Empagliflozin | 88 | 23 |
| Potassium Chloride | Potassium Chloride | 88 | 29 |
| Finasteride | Finasteride | 87 | 21 |
| Xarelto | Rivaroxaban | 87 | 12 |
| Meloxicam | Meloxicam | 85 | 35 |
| Bumetanide | Bumetanide | 83 | 28 |
| Eliquis | Apixaban | 82 | 20 |
| Glimepiride | Glimepiride | 82 | 31 |
| Famotidine | Famotidine | 77 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 19 |
| Trazodone Hcl | Trazodone Hcl | 76 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 22 |
| Tramadol Hcl | Tramadol Hcl | 73 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 20 |
| Carvedilol | Carvedilol | 68 | 19 |
| Furosemide | Furosemide | 67 | 24 |
| Enalapril Maleate | Enalapril Maleate | 56 | 16 |
| Valsartan | Valsartan | 54 | 15 |
| Atenolol | Atenolol | 53 | 15 |
| Mounjaro | Tirzepatide | 51 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 15 |
| Rybelsus | Semaglutide | 43 | 12 |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 14 |
| Benazepril Hcl | Benazepril Hcl | 38 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 38 | suppressed |
| Indapamide | Indapamide | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 12 |
| Prednisone | Prednisone | 36 | 24 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 11 |
| Azithromycin | Azithromycin | 21 | 18 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $754.28 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, MOUNJARO, Symbravo, TZIELD | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error